Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT04373369
Phase
PHASE2
Status
Terminated

Conditions

  • Extensive-stage Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vorolanib — DRUG
    Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.
  • Atezolizumab — DRUG
    Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.

Study Details

The purpose of the study is to determine whether adding vorolanib to atezolizumab will improve the length of time that participants are cancer-free after receiving standard chemotherapy.

Key Dates

Start date
Oct 7, 2020
Status verified
Oct 2025
Primary completion
Aug 18, 2022
Completion
Aug 11, 2025

Study Design

Enrollment
11 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vorolanib + Atezolizumab
    Consenting and eligible participants who have no evidence of tumor progression after 3 to 4 cycles of standard-of-care induction therapy will receive atezolizumab intravenously (IV) every 3 weeks and vorolanib by mouth daily.

Primary Outcome Measure

Kaplan Meier Estimate of Progression-free Survival (PFS) at 6 Months [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110-

Find similar trials in St Louis, MO

By research site
Washington University School of Medicine· St Louis, MO

Related Studies